According to Pixalate’s May 2025 rankings, ‘Sudoku’ is No. 1 on the Apple App Store, and ‘Pixel Art’ is at the top on the Google Play Store, within the ‘Video Gaming’ IAB app category in the United Kingdom (UK)
London, June 02, 2025 (GLOBE NEWSWIRE) — Pixalate, the leading global platform for ad fraud protection, privacy, and compliance analytics, today released the United Kingdom’s May 2025 Top Mobile Gaming Apps Rankings for Programmatic Advertising Traffic Quality on the Apple App Store and the Google Play Store.
The report ranks mobile apps in the ‘Video Gaming’ IAB app category based on their programmatic advertising traffic quality, as measured by Pixalate’s Publisher Trust Index (PTI). Pixalate has also released a United States (U.S.) version of the report.
The Pixalate Publisher Trust Index is published monthly, highlighting the top apps based on Pixalate’s proprietary technology and methodology.
UK Mobile PTI Rankings: Top ‘Gaming’ Apps (May 2025)
Apple App Store
- Sukdoku
- Blockudoku
- Scrabble GO
Google Play Store
- Pixel Art
- Jigsaw Puzzles
- Solitaire – Classic Card Game
Download the full rankings here.
Pixalate uses its proprietary algorithms to measure quality metrics, including invalid traffic (IVT, including ad fraud), Made For Advertising (MFA) risk, brand safety, ad density, viewability, reach, and more. The Publisher Trust Indexes span rankings for 235+ countries across all four global regions: North America, EMEA, APAC, and LATAM. They also provide breakdowns by 20+ different IAB taxonomy website categories. Pixalate’s methodology can be found at Publisher Trust Index: Methodology.
Pixalate’s data science team analyzed over 15 billion global open programmatic ad impressions across over 600k Google Play Store and Apple App Store mobile apps in the ‘Video Gaming’ IAB category in May 2025 to compile this report.
Download the Reports
- US Publisher Trust Index – Top Games
- UK Publisher Trust Index – Top Games
About Pixalate
Pixalate is a global platform specializing in privacy compliance, ad fraud prevention, and digital ad supply chain data intelligence. Founded in 2012, Pixalate is trusted by regulators, data researchers, advertisers, publishers, ad tech platforms, and financial analysts across the Connected TV (CTV), mobile app, and website ecosystems. Pixalate is accredited by the MRC for the detection and filtration of Sophisticated Invalid Traffic (SIVT). pixalate.com
DISCLAIMER
The Publisher Trust Index (PTI) reflects Pixalate’s opinions with respect to factors that Pixalate believes may be useful to the digital media industry. Our reports and indexes examine programmatic advertising activity on mobile apps and Connected TV (CTV) apps. Any insights shared are grounded in Pixalate’s proprietary technology and analytics, which Pixalate is continuously evaluating and updating. Any references to outside sources in the Indexes and herein should not be construed as endorsements. Pixalate’s opinions are just that, opinions, which means that they are neither facts nor guarantees. This report is not intended to impugn the standing or reputation of any person, entity or app. Per the MRC, “’Fraud’ is not intended to represent fraud as defined in various laws, statutes and ordinances or as conventionally used in U.S. Court or other legal proceedings, but rather a custom definition strictly for advertising measurement purposes. Also per the MRC, “‘Invalid Traffic’ is defined generally as traffic that does not meet certain ad serving quality or completeness criteria, or otherwise does not represent legitimate ad traffic that should be included in measurement counts. Among the reasons why ad traffic may be deemed invalid is it is a result of non-human traffic (spiders, bots, etc.), or activity designed to produce fraudulent traffic.”
CONTACT: Nina Talcott ntalcott@pixalate.com
- CallTower Launches Entra Sync: Streamlining Microsoft Teams Provisioning and Management - June 25, 2025
- Essential Pharma strengthens Board with the appointment of Nicola Heffron as Non-Executive Director - June 25, 2025
- Actimed Therapeutics Enrolls First Patients in Phase 2a PROACT Study Programme to Assess S-pindolol benzoate in Obese Patients During and Post-GLP-1 Agonist Therapy - June 25, 2025
